[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"morbid-obesity-requiring-bariatric-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:morbid-obesity-requiring-bariatric-surgery":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100639410","investigation-of-the-effects-of-whole-body-vibration-application-on-muscle-functional-level-physical-fitness-and-respiratory-parameters-after-bariatric-surgery-100639410",false,"NCT07602959","Investigation of the Effects of Whole Body Vibration Application on Muscle Functional Level, Physical Fitness and Respiratory Parameters After Bariatric Surgery","Inclusion Criteria:\n\n* Having undergone bariatric surgery, At least 6 weeks have passed since bariatric surgery, Being between the ages of 18-65, Being diagnosed with obesity and having a BMI\\>35, There is no obstacle that restricts exercise\n\nExclusion Criteria:\n\n* Acute hernia, Thromboembolism, Steroid use, Cardiovascular, neurological, orthopedic disease, Presence of knee or hip prosthesis, History of non-traumatic fracture, Presence of pacemaker, Malignancy, Presence of kidney, liver or thyroid disease, Presence of arrhythmia, Pregnancy status, Presence of kidney stones, Presence of epilepsy, Presence of migraine, Presence of organ failure, Presence of acute infection, History of smoking, Presence of respiratory system disease",true,"ALL","18 Years","65 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","The aim of this study was to investigate the effects of whole body vibration on muscle functional level, physical fitness and respiratory parameters after bariatric surgery.\n\nHypotheses of the study:\n\nH1: TVV after bariatric surgery has an effect on the functional level of the muscle.\n\nH2: TVV after bariatric surgery has an effect on physical fitness. H3: TVV after bariatric surgery has an effect on respiratory parameters. H4: TVV after bariatric surgery has an effect on quality of life. H5: TVV after bariatric surgery has an effect on body composition. H6: TVV after bariatric surgery has an effect on biochemical parameters.\n\nPatients will be divided into 3 randomized controlled groups. Whole body vibration application group, resistance exercise group and control group.\n\nThe whole body vibration group will exercise on the device 3 days a week. Resistance exercise group will exercise with resistance band 3 days a week. All exercises will last 6 weeks. The whole body vibration, resistance exercise and control groups will be recommended to walk 7 days a week.",[27,28,29],"Obesity & Overweight","Morbid Obesity","Morbid Obesity Requiring Bariatric Surgery",[31,32,33,34,35,36],"bariatric surgery","whole body vibration","resistance exercise","physical fitness","respiration","functional level of muscle","NOT_YET_RECRUITING","2026-05-16",{"date":40,"type":41},"2026-05-22","ACTUAL",{"date":43,"type":21},"2026-05-30",{"date":45,"type":21},"2026-09-01",{"name":47,"class":48},"Kirsehir Ahi Evran Universitesi","OTHER",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":56,"targetDuration":58,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100636389","can-pre-operative-lean-mass-predict-weight-loss-after-roux-en-y-gastric-bypass-100636389","NCT07565051","Can Pre-operative Lean Mass Predict Weight Loss After Roux-en-Y Gastric Bypass?","FLAG","Inclusion Criteria:\n\n* Patients ≥ 18 years AND\n* Meeting inclusion criteria for RYGB (www.smob.ch): BMI ≥35 kg\u002Fm2, failure of weight-reducing programs over 2 years (for patients with a BMI ≥50 kg\u002Fm2, 1 year), understanding of the necessity to change the lifestyle and eating habits post-operatively, signed consent for lifelong post-operative follow-up in a recognized bariatric center AND\n* Scheduled RYGB at the HUG OR previous RYGB at the HUG with a present follow-up in Clinical Nutrition and dietetics at the HUG AND\n* Understanding French\n\nExclusion Criteria:\n\n* Inability or refusal to give consent.\n* Planification for another type of bariatric surgery than RYGB\n* Contra-indications to bariatric surgery as stated under www.smob.ch: insufficient nutritional knowledge in nutrition to lose weight, pregnancy, kidney failure (Creatinine ≥ 300 umol\u002Fl without dialysis, Crohn's disease, active cancer or remission \\\u003C 2 years, active psychiatric disease, substance abuse (alcohol, cannabis, opioids), absence of compliance, lack of understanding of the requirements and necessary lifestyle changes reported by physician or dietician.",{"count":57,"type":21},91,"5 Years","OBSERVATIONAL","The goal of this observational study is to evaluate whether preoperative fat-free mass predicts post-operative weight loss in patients undergoing Roux-En-Y gastric bypass. The primary objective of this study is to evaluate whether preoperative fat-free mass predicts weight loss in the two years following RYGB.\n\nThe investigators will collect the following data, assessed as part of routine follow-up:\n\n* height, weight, hip and waist circumferences\n* body composition by bioimpedance analysis and dual energy-X-ray absorptiometry\n* Muscle strength and physical activity\n* Nutritional parameters: resting energy expenditure, eating behavior and digestive tolerance\", plasma micronutrient status. .\n* Cardiovascular risk factors: fasting glucose, blood levels of Hb1Ac, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, blood pressure\n* Co-morbidities: joint pain and arthritis, sleep apnea, gastro-oesophageal reflux, metabolic dysfunction-associated fatty liver disease (MAFLD), cancer, stroke, heart attack.\n\nQuality of life: quality of life by the \"Bariatric Analysis and Reporting Outcome (BAROS) questionnaire\", symptoms of dumping syndrome by the \"Sigstad diagnostic score system\" Birthdate, birthweight and term of their children",[29],[63,64,65,66,67,68],"obesity","gastric bypass","body composition","bone mineral density","handgrip strength","sarcopenic obesity","RECRUITING","2026-05-04",{"date":72,"type":41},"2026-05-08",{"date":74,"type":41},"2025-08-18",{"date":76,"type":21},"2032-08-18",{"name":78,"class":48},"University Hospital, Geneva",1,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":92,"conditions":93,"keywords":100,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":122},"100598619","phase-4-effect-of-lidocaine-dexmedetomidine-on-pain-inflammation-and-oxidative-stress-after-bariatric-surgery-100598619","NCT07073846","Effect of Lidocaine-Dexmedetomidine on Pain, Inflammation, and Oxidative Stress After Bariatric Surgery.","Efficacy of Lidocaine-Dexmedetomidine Combination Therapy in Reducing Post-Operative Pain, Inflammatory Response, and Oxidative Stress in Patients Undergoing Bariatric Surgery","Inclusion Criteria:\n\n* Adults aged 18 - 60 years\n* Male or female\n* Elective laparoscopic bariatric surgery\n* Post-operative pathway: post-anaesthesia care unit (PACU) followed by standard ward, with an expected in-hospital stay ≥ 24 h\n* ASA physical-status II or III\n\nExclusion Criteria:\n\n* Use of any loco-regional anaesthetic technique during the peri-operative period (transversus abdominis plane, paravertebral, spinal, epidural, erector spinae, or other abdominal wall blocks).\n* Current substance abuse or illicit drug use.\n* Previous abdominal surgery within the last 6 months.\n* Known hypersensitivity or allergy to lidocaine, dexmedetomidine, amide local anaesthetics, or α₂-adrenergic agonists.\n* Congestive heart failure, significant bradyarrhythmia, second- or third-degree atrio-ventricular block without pacemaker, severe hypotension, or current therapy with Class I\u002FIII anti-arrhythmic drugs.\n* Estimated glomerular filtration rate (eGFR) \\\u003C 60 mL min-¹ 1.73 m-² (moderate-to-severe renal impairment).\n* Severe hepatic impairment (Child-Pugh C).\n* Pregnancy or lactation.\n* Chronic opioid consumption \\> 30 mg oral morphine equivalents per day for \\> 4 weeks\n* Active seizure disorder, myasthenia gravis, or other neurologic disease contraindicating lidocaine infusion.\n* Patient cannot communicate\n* Patient does not want to fill in the questionnaire\n* Participation in another interventional study within the past 30 days.\n* Intra-operative conversion to open surgery.\n* Insufficient biological sample for biomarker analysis.\n* Premature discontinuation of the study drug during surgery for any reason that, in the judgement of the treating anaesthesiologist or investigators, prevents adequate exposure or assessment of safety variables (e.g., major haemorrhage \\> 200 mL, anaphylactic shock, failed intubation, inability to extubate, severe metabolic\u002Frespiratory acidosis, transfer to ICU while intubated).","60 Years",{"count":89,"type":21},104,[91],"PHASE4","The goal of this randomized clinical trial is to find out whether giving an intravenous lidocaine + dexmedetomidine combination (LIDEX) during laparoscopic bariatric surgery can lower post-operative pain, inflammation, and oxidative stress in adults with obesity.\n\nThe main questions it aims to answer are:\n\n* Pain control: Does LIDEX reduce pain 24 hours after surgery, as measured with the International Pain Outcomes Questionnaire (IPOQ)?\n* Biomarkers: Does LIDEX lower blood levels of key inflammatory cytokines-interleukin-1 beta (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interleukin-10 (IL-10)-and oxidative-stress markers-malondialdehyde (MDA), the reduced\u002Foxidized glutathione ratio (GSH\u002FGSSG), superoxide dismutase (SOD), and catalase-compared with the individual drugs or saline placebo?\n\nResearchers will compare four groups: lidocaine alone, dexmedetomidine alone, LIDEX, and placebo (saline solution, a look-alike substance that contains no drug) to learn which approach works best.\n\nParticipants will:\n\n* Receive an intravenous infusion of their assigned study drug(s) during surgery.\n* Provide three small blood samples (before surgery, immediately after, and three hours after).\n* Complete a short pain questionnaire (IPOQ) 24 hours after surgery.",[29,94,95,96,97,98,99],"Postoperative Pain","Postoperative Pain Management","Postoperative Analgesia","Postoperative Adjuvant Treatment","Postoperative Inflammatory Markers","Postoperative Inflammatory Response",[101,102,103,104,105,106,107,108,109,110,111],"Bariatric Surgery","Laparoscopic Sleeve Gastrectomy","Laparoscopic Gastric Bypass","Pain Management","Lidocaine-Dexmedetomidine","Multimodal Analgesia","Inflammatory Cytokines","Oxidative Stress","Opioid-sparing Anesthesia","Enhanced Recovery (ERAS)","Postoperarive Oxidative Stress","2025-11-26",{"date":114,"type":41},"2025-11-28",{"date":116,"type":41},"2025-10-06",{"date":118,"type":21},"2027-07-01",{"name":120,"class":121},"Instituto Mexicano del Seguro Social","OTHER_GOV",2]